company background image
0PT

Prothena DB:0PT Stock Report

Last Price

€50.22

Market Cap

€2.7b

7D

-0.1%

1Y

65.2%

Updated

25 Jan, 2023

Data

Company Financials +

0PT Stock Overview

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.

0PT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Prothena Corporation plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prothena
Historical stock prices
Current Share PriceUS$50.22
52 Week HighUS$64.54
52 Week LowUS$21.60
Beta0.50
1 Month Change-6.24%
3 Month Change-15.79%
1 Year Change65.20%
3 Year Change305.00%
5 Year Change47.71%
Change since IPO924.90%

Recent News & Updates

Recent updates

Shareholder Returns

0PTDE BiotechsDE Market
7D-0.1%2.0%-0.9%
1Y65.2%14.1%-9.6%

Return vs Industry: 0PT exceeded the German Biotechs industry which returned 13.9% over the past year.

Return vs Market: 0PT exceeded the German Market which returned -8.7% over the past year.

Price Volatility

Is 0PT's price volatile compared to industry and market?
0PT volatility
0PT Average Weekly Movement8.3%
Biotechs Industry Average Movement5.4%
Market Average Movement5.2%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.3%

Stable Share Price: 0PT is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 0PT's weekly volatility has decreased from 15% to 8% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201282Gene Kinneyhttps://www.prothena.com

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease.

Prothena Corporation plc Fundamentals Summary

How do Prothena's earnings and revenue compare to its market cap?
0PT fundamental statistics
Market Cap€2.65b
Earnings (TTM)-€143.80m
Revenue (TTM)€4.74m

559.9x

P/S Ratio

-18.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
0PT income statement (TTM)
RevenueUS$5.15m
Cost of RevenueUS$120.75m
Gross Profit-US$115.59m
Other ExpensesUS$40.88m
Earnings-US$156.48m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.03
Gross Margin-2,242.82%
Net Profit Margin-3,036.03%
Debt/Equity Ratio0%

How did 0PT perform over the long term?

See historical performance and comparison